Karuna Therapeutics

Psychiatry drugs finally have pharma’s attention. Can they keep it?
BioPharma Dive
Tue, 04/9/24 - 05:50 pm
Karuna Therapeutics
schizophrenia
psychiatric disease
Karuna's captains set sail in new neuropsychiatric venture called Seaport Therapeutics
Fierce Biotech
Tue, 04/9/24 - 11:43 am
Karuna Therapeutics
Seaport Therapeutics
PureTech Health
funding
anxiety
depression
Psychosis: The Other Big Alzheimer’s Therapeutic Target
BioSpace
Tue, 04/2/24 - 11:46 am
Alzheimer's disease
Alzheimer's disease psychosis
Cerevel Therapeutics
Karuna Therapeutics
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
Karuna, Cerevel might be just the start of psychiatry drug M&A
BioPharma Dive
Tue, 01/23/24 - 11:17 am
M&A
Karuna Therapeutics
Cerevel Therapeutics
schizophrenia
AbbVie
Bristol Myers Squibb
Another big pharma competed for Karuna, submitting all-cash offer day before BMS deal announcement
Fierce Biotech
Mon, 01/22/24 - 10:17 pm
Karuna Therapeutics
Bristol Myers Squibb
M&A
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive
Fri, 12/22/23 - 09:44 am
Bristol Myers Squibb
Karuna Therapeutics
schizophrenia
M&A
KarXT
Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Fierce Biotech
Fri, 11/17/23 - 11:31 am
Karuna Therapeutics
KarXT
blood pressure
schizophrenia
Karuna submits schizophrenia drug for US approval
BioPharma Dive
Thu, 09/28/23 - 12:02 pm
Karuna Therapeutics
KarXT
schizophrenia
FDA
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
Top biotech licensing deals of Q1 2023
BioSpace
Thu, 03/30/23 - 11:03 am
biotech
licensing
Moderna Therapeutics
CytomX
Voyager Therapeutics
Neurocrine Biosciences
Kronos Bio
Genentech
Karuna Therapeutics
Goldfinch Bio
Royalty Pharma hands off $100M upfront for PureTech royalty on Karuna's schizophrenia hopeful
Endpoints
Thu, 03/23/23 - 11:49 am
Royalty Pharma
Karuna Therapeutics
KarXT
schizophrenia
PureTech
JPM Day 2: Highlights
BioSpace
Tue, 01/10/23 - 06:50 pm
JPMHC 2023
Relay Therapeutics
Sanofi
Scholar Rock
SAGE Therapeutics
Karuna Therapeutics
GSK
JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate
Fierce Biotech
Tue, 01/10/23 - 06:37 pm
JPMHC 2023
Karuna Therapeutics
drug launches
schizophrenia
KarXT
Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch
Fierce Biotech
Mon, 01/9/23 - 10:31 am
Karuna Therapeutics
schizophrenia
KarXT
drug launches
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Karuna switches CEOs ahead of FDA filing for schizophrenia drug
BioPharma Dive
Tue, 12/6/22 - 08:45 pm
Karuna Therapeutics
Pharma CEOs
schizophrenia
FDA
KarXT
3 Biopharmas on Buyout Watch
Motley Fool
Mon, 08/22/22 - 10:39 am
M&A
Axsome Therapeutics
Alnylam Pharmaceuticals
Karuna Therapeutics

Pages